New Delhi: New cases of corona in India are setting new records every day. At the same time, in the case of deaths, India is moving faster than other countries of the world. There is now good news about the Desi Corona Vaccine. The native corona vaccine being developed by Bharat Biotech has become the first phase of clinical trials with ‘Kovacin’. Now the drug regulator has also approved its second phase study.
The Subject Expert Committee has said that this time 380 people should be tried. The second phase of Covaxin (Covaxin) trials in humans could begin in the coming weeks, with ethics committee approval. On September 3, Joint Drugs Controller, Dr. S. Eshwara Reddy, said in a letter to Hyderabad-based company Bharat Biotech that an expert committee (expert committee) had called on the company to initiate the second phase of the investigation. Is studying In the second phase of the trial, this vaccine is being tested on 380 people.
Speaking of covaxine, 375 volunteers from 12 cities across the country took part in the first phase of the study. Covicin is the dominant drug in the domestic corona vaccine. Once the second phase of the cocaine process begins, it will join the vaccines from Zydus Cadila and Serum Institute of India, which are already undergoing a second phase study.
Also read, Asthma sufferers have problems with the changing season, this Ayurvedic tea will provide relief
How covaxine works
Let us know that covicin is an inactivated vaccine in which a virus is injected into the human body. Because of the non-pathogenic virus, a person does not get sick from this virus, but his body makes antibodies to fight this virus, so that the human body is already ready at the moment of attack from the real virus. Every step of the vaccine trial is very important.
In the first phase of the vaccine, the health of the volunteers is monitored and it appears that the vaccine dose does not cause any problems for the volunteers. After this, in the second phase of the trial, it is seen how effective this vaccine is for the virus and whether it can produce antibodies or not. In the third and final phase of the studies, the company sees how effective this vaccine is as a dose for a large population.
Click here to read other health news